The price of Hims & Hers Health Inc (NYSE:HIMS) shares last traded on Wall Street rose 0.37% to $56.77.
HIMS stock price is now 40.56% away from the 50-day moving average and 85.36% away from the 200-day moving average. The market capitalization of the company currently stands at $12.71B.
With the price target maintained at $30, TD Cowen recently Downgraded its rating from Buy to Hold for Hims & Hers Health Inc (NYSE: HIMS). On February 18, 2025, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock increasing its target price from $42 to quote $60, while ‘Citigroup’ rates the stock as ‘Sell’
In other news, Okupe Oluyemi, Chief Financial Officer sold 11,581 shares of the company’s stock on May 28 ’25. The stock was sold for $613,537 at an average price of $52.98. Upon completion of the transaction, the Chief Financial Officer now directly owns 39,153 shares in the company, valued at $2.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 27 ’25, Chief Legal Officer Boughton Soleil sold 3,233 shares of the business’s stock. A total of $180,628 was realized by selling the stock at an average price of $55.87. This leaves the insider owning 153,194 shares of the company worth $8.7 million. A total of 10.37% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $13.47 and a high of $72.98. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 1.59, and a quick ratio of 1.32.
The net profit margin was 9.21% and return on equity was 36.79% for HIMS.
